Recursion Pharmaceuticals, Inc. - Class A Common Stock — Flux de trésorerie (NASDAQ:RXRX)

Afficher le graphique complet Full chart

Financials

Flux de trésorerie liés aux activités d'exploitation -158.61 M-83.52 M-287.78 M-359.17 M-371.81 M -320.95 M Flux de trésorerie liés aux activités d'investissement -271.74 M193.25 M-10.23 M260.06 M-16.87 M -9.94 M Flux de trésorerie liés aux activités de financement 458.54 M154.34 M140.13 M304.12 M521.53 M 477.54 M Flux de trésorerie disponible -158.61 M-83.52 M-287.78 M-359.17 M-380.44 M -325.93 M

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering. The company is based in Salt Lake City, Utah. It was founded by Chris Gibson, Dean Li and Blake Borgeson.

RXRX

Financials

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Nouvelles

Two Months. $10 Million. A Sputnik Moment for AI.

L’action Recursion Pharmaceuticals atteint un plus bas sur 52 semaines à 2,79$

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Recursion T1 2026 : avancées de l’IA malgré des défis de revenus

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine (TEM)

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Résultats T1 2026 de Recursion : avancées du pipeline malgré un manque à gagner

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

AI Revolutionizing Biopharma: Faster, Better, Cheaper (NYSEARCA:XLV)

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know